Skip to main content

Advertisement

Log in

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50–70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.

    Article  CAS  PubMed  Google Scholar 

  2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7.

    Article  CAS  PubMed  Google Scholar 

  3. Kantarjian HM, O’Brien S, Cortes JE, Smith TL, Rios MB, Shan J, et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8(7):2167–76.

    CAS  PubMed  Google Scholar 

  4. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.

    Article  CAS  PubMed  Google Scholar 

  5. Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114(22):462a.

    Google Scholar 

  6. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. Cancer Res. 2005;65(11):4500–5.

    Article  PubMed  Google Scholar 

  7. Kim DW, Goh YT, Hsiao HH, Caguioa PB, Kim D, Kim WS, et al. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Int J Hematol. 2009;89(5):664–72.

    Article  CAS  PubMed  Google Scholar 

  8. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143–50.

    Article  CAS  PubMed  Google Scholar 

  9. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–9.

    Article  CAS  PubMed  Google Scholar 

  10. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110(7):2309–15.

    Article  CAS  PubMed  Google Scholar 

  11. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10):4143–50.

    Article  CAS  PubMed  Google Scholar 

  12. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207–13.

    Article  CAS  PubMed  Google Scholar 

  13. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204–12.

    Article  CAS  PubMed  Google Scholar 

  14. Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, et al. Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2009;89(3):332–41.

    Article  CAS  PubMed  Google Scholar 

  15. Okada M, Yamamoto K, Sakamaki H, Kobayashi Y, Ando K, Nakagawa Y, et al. Phase II study of dasatinib in patients with chronic phase CML-100 mg QD or 50 mg BID. Jap J Clin Hematol. 2008;49(9):256.

    Google Scholar 

  16. Khoury HJ, Goldberg SL, Mauro MJ, Stone R, Matloub Y, Chen T, et al. Dasatinib, lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia chronic-phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol. 2008;26:375s.

    Article  Google Scholar 

  17. Marin D, Milojkovic D, Bua M, de Lavallade H, Andreasson C, Sauuramba PR, et al. The use of dasatinib in chronic myeloid leukemia: some practical considerations. Clin Leuk. 2007;1(4):229–33.

    Article  CAS  Google Scholar 

  18. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.

    Article  CAS  PubMed  Google Scholar 

  19. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–11.

    Article  CAS  PubMed  Google Scholar 

  20. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51.

    Article  PubMed  Google Scholar 

  21. Tauchi T, Ohyashiki K. The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol. 2006;83(4):294–300.

    Article  CAS  PubMed  Google Scholar 

  22. Hochhaus A, Kantarjian HM, Baccarani M, Coutre PL, Haque A, Gallagher N, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronicphase (CP) or accelerated phase (AP). Haematologica. 2008;93(s1):56.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yukio Kobayashi.

Appendix: Participants

Appendix: Participants

National Cancer Center Hospital, Tokyo Metropolitan Komagome Hospital, Kyoto Prefectural University of Medicine, Tohoku University, Aichi Cancer Center, Hyogo College of Medicine, Yokohama City University Medical Center, Tokai University School of Medicine, The Jikei University School of Medicine, Saiseikai Maebashi Hospital, Tokyo Medical University, Sapporo Hokuyu Hospital, Japanese Red Cross Medical Center, Jiaikai Imamura Branch Hospital, Matsushita Memorial Hospital, Jichi Medical University, Nagoya University, Tokyo Women’s Medical University, Saitama Medical University, Okayama University, Nagasaki University, Hamamatsu University School of Medicine, Nagoya City University, Keio University, Nihon University, Kanazawa University, and Juntendo University School of Medicine.

About this article

Cite this article

Kobayashi, Y., Sakamaki, H., Fujisawa, S. et al. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Int J Hematol 93, 745–749 (2011). https://doi.org/10.1007/s12185-011-0864-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-011-0864-1

Keywords

Navigation